PTG 300 Drug

United States based Protagonist Therapeutics has dosed the first patient in a Phase II trial of PTG-300 for the treatment of #patients with beta #thalassemia.

The PTG-300 drug is actually an injectable hepcidin mimetic in clinical development, which has delivered encouraging results in the treatment of the disease.

Hepcidin is a natural peptide, in other words a critical regulatory hormone governing iron absorption, recycling and utilization by the body.

PTG-300 has been granted Orphan Drug designation in the U.S. and EU and has received Fast Track designation by the FDA for development in the treatment of beta thalassemia.

Initial results are expected to be reported by the company in the second half of 2019.

https://www.prnewswire.com/news-releases/protagonist-therapeutics-initiates-phase-2-trial-of-novel-hepcidin-mimetic-ptg-300-for-the-treatment-of-patients-with-beta-thalassemia-300775348.html